Docetaxel-d9 (RP-56976-d9) 是氘标记的 Docetaxel。 Docetaxel (RP-56976) 是一种微管解聚抑制剂，IC50 为 0.2 μM。多西他赛减弱 bcl-2 和 bcl-xL 基因表达的影响。 Docetaxel 在 G2/M 停止细胞周期并导致细胞凋亡。多西他赛具有抗癌活性。
货号:ajcx22334
CAS:940867-25-4
分子式:C43H44D9NO14
分子量：816.9
溶解度:Chloroform: Slightly Soluble,Methanol: Slightly Soluble
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Docetaxel-d₉is intended for use as an internal standard for the quantification of docetaxel by GC- or LC-MS. Docetaxel is a semisynthetic analog of paclitaxel that inhibits microtubule disassembly (IC₅₀= 0.2 μM) and inhibits cell replication (IC₅₀= 0.13 μM).¹It has proven more effective than taxol in preventing the proliferation of cancer cells.^1,2Docetaxel has potential applications in breast cancer and hormone-refractory prostate cancer.^3,4

1.Bissery, M.C., Guenard, D., Gueritte-Voegelein, F., et al.Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogueCancer Research514845-4852(1991) 2.Pazdur, R., Kudelka, A.P., Kavanagh, J.J., et al.The taxoids: Paclitaxel (Taxolr) and docetaxel (Taxoterer)Cancer Treatment Reviews19351-386(1993) 3.Mahon, K.L., Henshall, S.M., Sutherland, R.L., et al.Pathways of chemotherapy resistance in castration-resistant prostate cancerEndocrine-Related Cancer18R103-R123(2011) 4.Yao, X., Hosenpud, J., Chitambar, C.R., et al.A phase II study of concurrent docetaxel, epirubicin and cyclophospha-mide as a neoadjuvant chemotherapy regimen in patients with locally advanced breast cancerJournal of Cancer3145-151(2012)